Further research regarding biomarkers beyond PD-L1 expression and other characteristics of the tumor immune microenvironment will enhance our ability to predict which patients will respond to immune checkpoint inhibitor-containing treatments, allowing for more tailored therapy for each individual patient. This evidence concerns the gene CD274 and neoplasm.